Orgenesis Inc. (ORGS) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Orgenesis Inc. (ORGS) trades at $0.04 with AI Score 44/100 (Grade C). Orgenesis Inc. is a biotechnology company focused on cell and gene therapies, operating globally with a Point of Care (POCare) platform. Sector: Healthcare.
Price as of Jul 23, 2026 · Last analyzed: Mar 15, 2026Analyst Coverage for ORGS: ORGS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ORGS against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ORGS: 1/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Orgenesis Inc. (ORGS) Healthcare & Pipeline Overview
Orgenesis Inc. is a biotechnology firm specializing in cell and gene therapies through its proprietary Point of Care (POCare) platform. The company develops and delivers autologous therapies via closed, automated systems, positioning it within the evolving landscape of personalized medicine and decentralized healthcare solutions.
What Is the Investment Thesis for ORGS?
Orgenesis Inc. presents a unique investment opportunity within the cell and gene therapy space, driven by its innovative Point of Care (POCare) platform. The company's focus on autologous therapies and decentralized manufacturing aims to address key challenges in the delivery of advanced treatments. However, the company's negative profit margin of -10445.5% and gross margin of -1080.2% indicate significant financial challenges. The high beta of 4.07 suggests high volatility. Upcoming catalysts include the potential for regulatory approvals and commercialization of its POCare therapeutics. The success of its collaborative POCare network and the adoption of its closed, automated processing systems will be critical for long-term growth. Investors should carefully consider the company's financial performance and the risks associated with operating in the highly competitive biotechnology industry.
Based on FMP financials and quantitative analysis
ORGS Key Highlights
- Orgenesis Inc. operates in the high-growth cell and gene therapy market.
- The company's Point of Care (POCare) platform aims to decentralize the production of advanced therapies.
- Focus on autologous therapies reduces the risk of immune rejection.
- Negative profit margin of -10445.5% indicates significant financial challenges.
- High beta of 4.07 suggests high stock price volatility.
Who Are ORGS's Competitors?
ORGS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| HXBM Helix BioMedix, Inc. | $1.79 | +0.00% | 50 | |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.35% | $7.58M | 72 |
| BLRX BioLineRx Ltd. | $2.86 | +0.41% | $12.4M | 69 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.16 | +3.48% | $170M | 75 |
| CGEN Compugen Ltd. | $2.34 | -3.31% | $221M | 76 |
| SCPH scPharmaceuticals Inc. | $5.67 | +0.00% | $302M | 69 |
| ORTX Orchard Therapeutics plc | $16.70 | +0.30% | $380M | 69 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ORGS's Key Strengths?
- Proprietary Point of Care (POCare) platform.
- Focus on autologous therapies.
- Decentralized manufacturing model.
- Collaborative POCare network.
What Are ORGS's Weaknesses?
- Negative profit margin.
- High operating expenses.
- Limited commercialized products.
- Reliance on partnerships for growth.
What Could Drive ORGS Stock Higher?
- Regulatory approvals for POCare therapeutics.
- Expansion of POCare network.
- Strategic partnerships with pharmaceutical companies.
- Technological advancements to enhance POCare platform.
What Are the Key Risks for ORGS?
- Financial-distress signal — its Altman Z-Score of -19.19 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Competition from established pharmaceutical companies.
- Regulatory hurdles and delays.
- Technological obsolescence.
- Negative profit margin.
- High operating expenses.
What Are the Growth Opportunities for ORGS?
- Expansion of POCare Network: Orgenesis has the opportunity to expand its collaborative POCare network by partnering with hospitals and research institutions globally. This expansion would increase the accessibility of its cell and gene therapies, driving revenue growth. The global cell therapy market is projected to reach $8.28 billion in 2024 and is expected to grow. Timeline: Ongoing.
- Regulatory Approvals: Securing regulatory approvals for its pipeline of POCare therapeutics represents a significant growth opportunity. Successful approvals would validate the efficacy and safety of its therapies, leading to increased adoption and market penetration. The timeline for regulatory approvals varies depending on the specific therapy and regulatory pathway. Timeline: Upcoming.
- Strategic Partnerships: Forming strategic partnerships with pharmaceutical companies and other healthcare providers can accelerate the development and commercialization of its therapies. These partnerships can provide access to funding, expertise, and distribution channels. The timeline for forming strategic partnerships is dependent on identifying suitable partners and negotiating mutually beneficial agreements. Timeline: Ongoing.
- Technological Advancements: Investing in technological advancements to enhance its POCare platform can improve the efficiency and scalability of its manufacturing processes. This includes automation, closed systems, and advanced analytics. The timeline for implementing technological advancements is dependent on the specific technology and the availability of resources. Timeline: Ongoing.
- Geographic Expansion: Expanding its operations into new geographic markets represents a significant growth opportunity. This includes establishing POCare centers in regions with unmet medical needs and growing demand for advanced therapies. The timeline for geographic expansion is dependent on market analysis, regulatory approvals, and resource allocation. Timeline: Ongoing.
What Opportunities Does ORGS Have?
- Expansion of POCare network.
- Regulatory approvals for POCare therapeutics.
- Strategic partnerships with pharmaceutical companies.
- Geographic expansion into new markets.
What Threats Does ORGS Face?
- Competition from established pharmaceutical companies.
- Regulatory hurdles and delays.
- Technological obsolescence.
- Economic downturns affecting healthcare spending.
What Are ORGS's Competitive Advantages?
- Proprietary Point of Care (POCare) platform.
- Closed and automated processing systems.
- Collaborative POCare network.
- Focus on autologous therapies.
What Does ORGS Do?
Orgenesis Inc., established in 2008 and headquartered in Germantown, Maryland, is a biotechnology company dedicated to advancing cell and gene therapies. Originally named Business Outsourcing Service, Inc., the company rebranded to Orgenesis Inc. in August 2011, marking a strategic shift towards the healthcare sector. Orgenesis focuses on developing and deploying its Point of Care (POCare) platform, a comprehensive system designed for the localized production and delivery of advanced therapies. This platform includes a pipeline of licensed POCare therapeutics, which are processed and produced in closed, automated POCare technology systems. These systems are integrated within a collaborative POCare network, enabling the efficient and compliant manufacturing of therapies near the patient's point of care. The company's primary focus is on autologous therapies, where a patient's own cells are used for treatment, thereby reducing the risk of rejection and enhancing therapeutic efficacy. Orgenesis's approach involves developing customized processes and systems for each therapy, ensuring that the production is validated for compliant manufacturing. This decentralized model aims to improve patient access to advanced therapies, reduce costs, and enhance treatment outcomes.
What Products and Services Does ORGS Offer?
- Develops Point of Care (POCare) platform for cell and gene therapies.
- Focuses on autologous therapies using patient's own cells.
- Creates closed and automated processing systems for therapy production.
- Establishes collaborative POCare networks for decentralized manufacturing.
- Aims to improve patient access to advanced therapies.
- Validates processes for compliant production near the patient.
How Does ORGS Make Money?
- Develops and licenses POCare therapeutics.
- Generates revenue through the sale of POCare technology systems.
- Forms partnerships with hospitals and research institutions.
- Provides training and support for POCare network members.
What Industry Does ORGS Operate In?
Orgenesis Inc. operates within the rapidly evolving cell and gene therapy market, a sector characterized by significant innovation and growth potential. The industry is driven by advancements in biotechnology and a growing demand for personalized medicine. Companies like Orgenesis are at the forefront of developing novel therapies for a range of diseases, including cancer and genetic disorders. The competitive landscape includes established pharmaceutical companies, as well as emerging biotech firms, all vying for market share. Orgenesis's Point of Care (POCare) platform differentiates it by enabling decentralized manufacturing, potentially reducing costs and improving patient access. The market is expected to continue to grow, driven by increasing regulatory approvals and commercialization of new therapies.
Who Are ORGS's Key Customers?
- Hospitals and medical centers.
- Research institutions and universities.
- Pharmaceutical companies.
- Patients requiring cell and gene therapies.
F-Score 2/9Financial Health
Orgenesis Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -19.19 places it in the distress zone, a signal of elevated financial risk.
How Orgenesis Inc. Is Valued
Relative to its peer group, ORGS's quantitative score of 44/100 is below the peer average of 67/100.
Net buyingInsider Activity
The most recent 10 insider filings for Orgenesis Inc. break down as 0 sales and 10 purchases. On net that is roughly 253K shares acquired (about $260K) — insiders putting money in tends to read as conviction.
ORGS Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Orgenesis' future, indicating a belief in their growth potential.
- Positive community sentiment has emerged around their innovative cell and gene therapies, sparking interest among investors.
- Recent collaborations and partnerships have positioned Orgenesis favorably within the biotech sector, enhancing its market visibility.
- The company's focus on expanding its manufacturing capabilities aligns with increasing demand for personalized medicine, which could drive future growth.
Bear Case
- Concerns about regulatory hurdles in the biotech industry may create uncertainty around Orgenesis' product approvals and timelines.
- Social sentiment has shown some skepticism regarding the company's ability to scale its operations effectively amidst competition.
- Recent market developments have highlighted challenges in securing funding for biotech ventures, raising questions about Orgenesis' financial stability.
- Some community voices express caution due to the volatility often associated with biotech stocks, which can lead to sudden price swings.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ORGS Latest News
No recent news available for ORGS.
ORGS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ORGS.
Price Targets
Wall Street price target analysis for ORGS.
ORGS MoonshotScore
What does this score mean?
The MoonshotScore rates ORGS 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Vered Caplan
CEO
Vered Caplan serves as the CEO of Orgenesis Inc., bringing extensive experience in the biotechnology and healthcare sectors. Her background includes leadership roles in various companies focused on cell and gene therapies. She has a proven track record of driving innovation and commercializing novel therapies. Caplan's expertise spans strategic planning, business development, and operational management. She is committed to advancing Orgenesis's mission of delivering accessible and affordable cell and gene therapies to patients worldwide.
Track Record: Under Vered Caplan's leadership, Orgenesis Inc. has focused on expanding its Point of Care (POCare) platform and establishing strategic partnerships to accelerate the development and commercialization of its therapies. Key milestones include advancing the company's pipeline of POCare therapeutics and expanding its collaborative POCare network. Caplan has also overseen efforts to improve the efficiency and scalability of Orgenesis's manufacturing processes.
ORGS OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Orgenesis Inc. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier are often subject to less stringent regulations and may have limited financial information available to the public. Trading on the OTC Other tier carries higher risks compared to exchanges like NYSE or NASDAQ due to the potential for less transparency and regulatory oversight.
- OTC Tier: OTC Other
- Limited financial disclosure.
- Higher price volatility.
- Lower trading volume.
- Potential for fraud or manipulation.
- Less regulatory oversight.
- Verify the company's financial statements.
- Research the company's management team.
- Review the company's business plan.
- Assess the company's competitive landscape.
- Check for any regulatory actions or legal issues.
- Understand the risks associated with OTC trading.
- Consult with a financial advisor.
- Established Point of Care (POCare) platform.
- Focus on autologous therapies.
- Collaborative POCare network.
- Experienced management team.
- Partnerships with hospitals and research institutions.
What Investors Ask About Orgenesis Inc. (ORGS) — Healthcare
What does the AI Score mean for ORGS?
ORGS holds an AI Score of 44/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Orgenesis Inc. is a biotechnology company focused on cell and gene therapies, operating globally with a Point of Care (POCare) platform. The company develops autologous therapies using closed …
What does Orgenesis Inc. do?
Orgenesis Inc. is a biotechnology company focused on developing and commercializing cell and gene therapies through its proprietary Point of Care (POCare) platform. The company's business model revolves around creating a decentralized network of treatment centers where therapies can be produced and administered locally. This approach aims to reduce costs, improve patient access, and enhance treatment outcomes.
What do analysts say about ORGS stock?
Analyst coverage of Orgenesis Inc. (ORGS) stock is limited due to its OTC listing and smaller market capitalization. Key valuation metrics such as price-to-earnings (P/E) ratio are currently not meaningful due to negative earnings. Growth considerations center around the successful expansion of its POCare network, regulatory approvals for its therapeutic pipeline, and strategic partnerships. Investors should conduct thorough due diligence and consider the risks associated with investing in OTC-listed companies.
What are the main risks for ORGS?
The main risks for Orgenesis Inc. include its negative profit margin and high operating expenses, which raise concerns about its financial sustainability. Regulatory hurdles and delays in obtaining approvals for its POCare therapeutics pose a significant risk. Competition from larger, more established pharmaceutical companies with greater resources is also a key challenge.
What are the key factors to evaluate for ORGS?
Orgenesis Inc. (ORGS) holds an AI score of 44/100 (low). Not financial advice.
How frequently does ORGS data refresh on this page?
ORGS's price was last updated on Jul 23, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ORGS's recent stock price performance?
Orgenesis Inc. (ORGS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary Point of Care (POCare) platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ORGS overvalued or undervalued right now?
Orgenesis Inc. (ORGS) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research ORGS before investing?
Before investing in Orgenesis Inc. (ORGS), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is limited and may not be up-to-date.
- OTC market carries higher risks than major exchanges.